Apadamtase alfa · Adzynma
Protein / enzyme therapeutic
Also known as TAK-755
Evidence outlook
Approved: prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- ADZYNMA is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Acute Ischemic Stroke: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Apadamtase Alfa (Adzynma): this drug | Phase 2 | Protein / enzyme therapeutic | ADAMTS13 | not yet graded | No reviewed efficacy summary in this indication | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Reliable signal | NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants | |
| Edaravone (TTYP01) | Phase 3 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Rinvecalinase Alfa | Phase 2/3 | Protein / enzyme therapeutic | Tissue kallikrein-1 (KLK1) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4029 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7450 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8829 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Adzynma (Apadamtase alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent